Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Imlifidase før nyretransplantasjon hos svært sensibiliserte barn (DINKY)

6. november 2026 oppdatert av: Hansa Biopharma AB

En enarms, multisenterforsøk for å evaluere effektiviteten og sikkerheten til imlifidase hos svært sensibiliserte barn (1-17 år) som får en nyretransplantasjon med positiv kryssmatch mot en levende eller avdød donor konvertert til negativ etter Imlifidase-behandling

The goal of this clinical trial is to learn about the efficacy and safety of imlifidase in highly sensitized paediatric patients, 1-17 years old, with end stage renal disease (ESRD).

The main questions it aims to answer are:

  • Does imlifidase treatment result in crossmatch conversion that enables transplantation?
  • How is the function of the transplanted kidney?

The participants will be hospitalised in accordance with the normal routines for transplanted patients. The patients will receive medication to prevent rejection of the donor kidney, and because such treatment make the body more vulnerable medications to prevent infections.

Studieoversikt

Status

Rekruttering

Intervensjon / Behandling

Detaljert beskrivelse

After being informed about the study and potential risks, all patients giving written informed consent will undergo pre-screening to determine eligibility for study entry.

The trial will include highly sensitised ESRD paediatric patients (1-17 years). The patients have previously undergone desensitization unsuccessfully or have an anti-HLA antibody status deemed too difficult to make a successful desensitization using other experimental methods.

A screening visit will take place when an organ offer has been placed for a final check of the patients' eligibility for study participation.

All patients included in the trial will be desensitized with imlifidase to convert the positive XM to negative and then transplanted with either a kidney from a deceased donor (DD) or a living donor (LD).

Patients will be hospitalised in accordance with the normal routines for transplanted patients at each clinic.

Following transplantation, the patients will receive induction therapies, rejection prophylaxis, and maintenance immunosuppressive therapies.

The patients will be closely monitored for any signs of antibody-mediated rejections (AMRs).

The duration of the interventional trial period after an organ has been offered will be 6 months for each patient. The trial includes a follow-up part to collect long-term efficacy and safety data up to 5 years after the transplantation.

Studietype

Intervensjonell

Registrering (Antatt)

10

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Helsinki, Finland, 00290
        • Tilbaketrukket
        • HUS, Helsinki University Hospital
      • Paris, Frankrike, 75019
        • Rekruttering
        • Robert Debre University Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Julien Hogan, Professor
      • Rome, Italia, 00165
        • Har ikke rekruttert ennå
        • Ospedale Pediatrico Bambino Gesu
        • Ta kontakt med:
        • Hovedetterforsker:
          • Raffaella Labbadia, MD
      • Barcelona, Spania, 08035
        • Rekruttering
        • Hospital Unviersitari Vall d'Hebron, Nefrología Pediátrica
        • Hovedetterforsker:
          • Gema Ariceta, MD
        • Ta kontakt med:
      • Barcelona, Spania, 08950
        • Har ikke rekruttert ennå
        • Hospital Sant Joan De Deu Barcelona
        • Ta kontakt med:
        • Hovedetterforsker:
          • Yolanda Calzada, MD
      • London, Storbritannia, WC1N 3JH
        • Rekruttering
        • Great Ormond Street Hospital for Children NHS Foundation Trust
        • Ta kontakt med:
          • S Marks, MD
        • Hovedetterforsker:
          • S Marks, MD
    • Stockholm County
      • Huddinge, Stockholm County, Sverige, SE-141 86

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

1 år til 17 år (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Signed Informed Consent obtained from patient/parent/legal guardian/independent witness (depending on patient's age) before any trial-related procedures
  2. Highly sensitised patient with panel reactive antibodies (PRA) ≥80%
  3. Male or female patient between the age of 1 to 17 years (up to the day before the 18th birthday) at the time of screening
  4. Patient with end-stage renal disease (ESRD) and waiting for a renal transplant from a living or deceased donor
  5. Patient must be transplantable (including size mismatch) at the time of obtaining informed consent for trial participation
  6. Patients who have previously undergone desensitisation unsuccessfully with plasmapheresis/IVIg/anti-CD20 or have an anti-HLA antibody status deemed too difficult to make a successful desensitisation (judgement based on physicians' previous experience with similar patients)
  7. Positive crossmatch (XM) test determined by flow cytometry crossmatch (FCXM) and/or complement-dependent cytotoxicity crossmatch (CDCXM) tests against the donor. For the DD patients, if physical XM tests are not practically possible due to lack of time, patients may be included on a virtual crossmatch (vXM) predictive of a positive XM test.
  8. Willingness and ability to comply with the protocol as judged by the investigator

Exclusion Criteria:

  1. Previous treatment with imlifidase
  2. IVIg treatment within 28 days prior to imlifidase treatment
  3. Desensitisation treatment(s) within 1 month prior to the current transplantation
  4. Hypersensitivity to the active substance (imlifidase) or to any of the excipients and to other immunosuppressive drugs specified in the protocol
  5. Ongoing serious infections
  6. Present, or history of, thrombotic thrombocytopenic purpura (TTP), or known familial history of TTP
  7. At the time of transplantation: severe other condition requiring treatment and close monitoring e.g. cardiac failure ≥ grade 4 (New York Heart Association), unstable coronary disease, active peripheral vascular disease, proven hypercoagulable conditions/events or oxygen dependent respiratory disease
  8. Malignancy within 3 years prior to transplantation
  9. ABO blood group incompatible transplantations (A2 and A2B kidneys will not be accepted for B recipients)
  10. Any other reason that, in the view of the investigator, precludes transplantation
  11. Breast feeding or pregnancy, if applicable
  12. Woman of fertile age and sexually active without adequate contraceptive measures to avoid pregnancy during the interventional trial period (i.e. up to 6 months after transplantation)
  13. Suspicion of Covid-19 infection or positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test
  14. Positive serology for human immunodeficiency virus (HIV)
  15. Clinical signs of hepatitis B virus (HBV), hepatitis C virus (HCV), cytomegalovirus (CMV), or Epstein Barr virus (EBV) infection
  16. Donor with positive serology for HIV, HBV, HCV or CMV to a patient with negative serology (mismatch serology). Mismatch serology for EBV in accordance with center specific standard procedures for transplantation of EBV negative recipients and at investigator's discretion.
  17. Clinically relevant active infection(s) as judged by the investigator
  18. Tuberculosis or history of tuberculosis
  19. Use of other investigational agents within 5 terminal elimination half-lives prior to the transplantation
  20. Contemporaneous participation in medical device studies
  21. Known mental incapacity or language barriers precluding patients'/parents'/legal guardians' adequate understanding of the informed consent information and the trial activities
  22. Inability by the judgement of the investigator to participate in the trial for any other reason

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Imlifidase

Imlifidase is administered intravenously as one infusion of 0.25 mg/kg over 15 minutes within 24 hours prior to transplantation.

Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.

Andre navn:
  • IdeS, HMED-IdeS

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Proportion of patients with conversion of a positive crossmatch test to negative within 24 hours after start of imlifidase treatment
Tidsramme: From start of imlifidase administration to 24 hours

Immunoglobulins (IgG) including donor specific antibodies (DSAs) are rapidly and efficiently cleaved by imlifidase. A conversion of a positive to a negative XM will enable transplantation.

From start of imlifidase administration to 24 hours

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Transplantatoverlevelse (dødsensurert) inntil 5 år etter transplantasjon
Tidsramme: Fra 6 måneder til 5 år
Fra 6 måneder til 5 år
Transplantasjonsfeilfri overlevelse inntil 5 år etter transplantasjon
Tidsramme: Fra 6 måneder til 5 år
Fra 6 måneder til 5 år
Pasientoverlevelse inntil 5 år etter transplantasjon
Tidsramme: Fra 6 måneder til 5 år
Fra 6 måneder til 5 år
Andel pasienter med dialyseavhengighet inntil 5 år etter transplantasjon
Tidsramme: Fra 6 måneder til 5 år
Fra 6 måneder til 5 år
Renal function up to 5 years after transplantation as assessed by estimated glomerular filtration rate (eGFR)
Tidsramme: From pre-dose imlifidase up to 5 years

eGFR is a measure of kidney function. Reduced kidney function is characterised by a decreased eGFR value.

From pre-dose imlifidase up to 5 years
Renal function up to 5 years after transplantation as assessed by serum/plasma creatinine levels
Tidsramme: From pre-dose imlifidase up to 5 years

Creatinine is a measure of kidney function. Reduced kidney function is characterised by an increased value.

From pre-dose imlifidase up to 5 years
Renal function up to 5 years after transplantation as assessed by serum/plasma cystatin C levels
Tidsramme: From pre-dose imlifidase up to 5 years

Cystatin C is a measure of kidney function. Reduced kidney function is characterised by an increased value.

From pre-dose imlifidase up to 5 years
Renal function up to 5 years after transplantation as assessed by proteinuria
Tidsramme: From pre-dose imlifidase up to 5 years

Proteinuria (protein/creatinine ratio in urine) is a measure of kidney function. Reduced kidney function is characterised by an increased value.

From pre-dose imlifidase up to 5 years
DSA levels up to 5 years after transplantation
Tidsramme: From pre-dose imlifidase up to 5 years

Donor specific antibodies (DSAs) are antibodies in the recipient directed against the transplanted organ.

From pre-dose imlifidase up to 5 years
Frequency of delayed graft function (DGF)
Tidsramme: From transplantation up 7 days after transplantation

DGF is defined as 'Need for dialysis within 7 days of transplantation' in "Delayed graft function in kidney transplantation: developing drugs for prevention, guidance for industry", FDA 2019.

Frequency of patients having DGF in accordance with this definition will be presented.

From transplantation up 7 days after transplantation
Length of DGF
Tidsramme: From transplantation up 7 days after transplantation

DGF is defined as 'Need for dialysis within 7 days of transplantation' in "Delayed graft function in kidney transplantation: developing drugs for prevention, guidance for industry", FDA 2019.

The duration of DGFs in accordance with this definition will be presented.

From transplantation up 7 days after transplantation
Imlifidase Pharmacokinetics (AUC)
Tidsramme: From pre-dose imlifidase up to Day 15

AUC = Area under the imlifidase plasma concentration versus time curve.

From pre-dose imlifidase up to Day 15
Imlifidase Pharmacokinetics (Cmax)
Tidsramme: From pre-dose imlifidase up to Day 15

Cmax = Maximum observed plasma concentration of imlifidase following dosing.

From pre-dose imlifidase up to Day 15
Imlifidase Pharmacokinetics (tmax)
Tidsramme: From pre-dose imlifidase up to Day 15

tmax = Time point for maximum observed plasma concentration of imlifidase following dosing

From pre-dose imlifidase up to Day 15
Imlifidase Pharmacokinetics (t1/2)
Tidsramme: From pre-dose imlifidase up to Day 15

t1/2 = Terminal half-life of imlifidase.

From pre-dose imlifidase up to Day 15
Imlifidase Pharmacokinetics (CL)
Tidsramme: From pre-dose imlifidase up to Day 15

CL = Clearance of imlifidase.

From pre-dose imlifidase up to Day 15
Imlifidase Pharmacokinetics (Vz)
Tidsramme: From pre-dose imlifidase up to Day 15

Vz = Volume of distribution during the elimination phase

From pre-dose imlifidase up to Day 15
Imlifidase Pharmacodynamic (PD) profile up to 9 days after imlifidase treatment
Tidsramme: From pre-dose imlifidase up to Day 10

PD is assessed as serum concentrations of intact IgG and its fractions following infusion.

From pre-dose imlifidase up to Day 10
Immunogenicity profile of imlifidase up to 5 years after imlifidase treatment
Tidsramme: From pre-dose imlifidase up to 5 years

Immunogenicity is assessed as serum concentration of anti-imlifidase IgG (ADA).

From pre-dose imlifidase up to 5 years
Proportion of patients with biopsy- and serology (DSA)-confirmed AMR up to 5 years after transplantation
Tidsramme: From transplantation up to 5 years

Banff scores (Loupy et al. 2020) will be used for biopsy evaluation.

From transplantation up to 5 years
Proportion of patients with biopsy confirmed cell-mediated rejection (CMR) up to 5 years after transplantation
Tidsramme: From transplantation up to 5 years

Banff scores (Loupy et al. 2020) will be used for biopsy evaluation.

From transplantation up to 5 years

Andre resultatmål

Resultatmål
Tidsramme
Sikkerhet vurdert som andel pasienter med infusjonsrelaterte reaksjoner innen 48 timer etter imlifidase-infusjon
Tidsramme: Fra start av imlifidase-infusjon opptil 48 timer
Fra start av imlifidase-infusjon opptil 48 timer
Sikkerhet vurdert som andel av pasienter med alvorlige eller alvorlige infeksjoner innen 30 dager etter imlifidase -behandling
Tidsramme: Fra start av Imlifidase -infusjon opp til 30 dager
Fra start av Imlifidase -infusjon opp til 30 dager

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Clinical Operations, Hansa Biopharma AB

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

2. juni 2023

Primær fullføring (Antatt)

28. februar 2027

Studiet fullført (Antatt)

31. august 2031

Datoer for studieregistrering

Først innsendt

23. februar 2023

Først innsendt som oppfylte QC-kriteriene

23. februar 2023

Først lagt ut (Faktiske)

3. mars 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

6. november 2026

Sist bekreftet

1. april 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere